Takeda made Orzeyful (oveporexton) available in Japan and China for narcolepsy type 1, while Insmed launched Brinsupri ...
US artificial intelligence (AI) company OpenAI has acquired Orchestra Bio, adding a platform for coordinating drug ...
UK biotechnology Touchlight, which is specializing in cell-free DNA manufacturing, today announces that Karen Fallen is ...
Median annual net drug launch prices in the USA reached $257,000 in 2025, remaining 35% above their 2022 level despite a ...
US biotech Rapport Therapeutics (Nasdaq: RAPP) plans to begin two Phase III trials of RAP-219 in acute bipolar mania in the ...
Russian pharmaceutical manufacturers and global drugmakers operating in the local market have called on the need of ...
ViiV Healthcare, the HIV company majority owned by GSK, today announced that Deborah Waterhouse will step down as chief ...
Xoc Pharmaceuticals is a privately-held, early-stage, biopharmaceutical company focused on the development of innovative therapeutics. The company designs novel products “from the ground up” by ...
A San Diego-based biotech company focused on advancing cell, gene, and mRNA-based therapies. Artis emerged from stealth in April 2025 with the acquisition of Landmark Bio, a prominent cell and gene ...
US biotech major Amgen and the UK’s AstraZeneca today announced full results from the Phase III CROSSING trial of Tezspire ...
US drugmaker Collegium Pharmaceuticals announced a settlement agreement between the company and Germany’s Grunenthal.
Japan’s largest drugmaker Takeda has announced new data from VERDICT showing that treating adults with intravenous Entyvio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results